Literature DB >> 18657585

Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.

Robert J Cybulski1, Patrick Sanz, Dennis McDaniel, Steve Darnell, Robert L Bull, Alison D O'Brien.   

Abstract

Inactivated Bacillus anthracis spores given with protective antigen (PA) contribute to immunity against anthrax in several animal models. Antiserum raised against whole irradiated B. anthracis spores has been shown to have anti-germination and opsonic activities in vitro. Based on these observations, we hypothesized that surface-exposed spore proteins might serve as supplemental components of a PA-based anthrax vaccine. The protective anti-spore serum was tested for reactivity with recombinant forms of 30 proteins known, or believed to be, present within the B. anthracis exosporium. Eleven of those proteins were reactive with this antiserum, and, subsequently a subset of this group was used to generate rabbit polyclonal antibodies. These sera were evaluated for recognition of the immunogens on intact spores generated from Sterne strain, as well as from an isogenic mutant lacking the spore surface protein Bacillus collagen-like antigen (BclA). The data were consistent with the notion that the antigens in question were located beneath BclA on the basal surface of the exosporium. A/J mice immunized with either the here-to-for hypothetical protein p5303 or the structural protein BxpB, each in combination with subprotective levels of PA, showed enhanced protection against subcutaneous spore challenge. While neither anti-BxpB or anti-p5303 antibodies reduced the rate of spore germination in vitro, both caused increased uptake and lead to a higher rate of destruction by phagocytic cells. We conclude that by facilitating more efficient phagocytic clearance of spores, antibodies against individual exosporium components can contribute to protection against B. anthracis infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657585      PMCID: PMC2586003          DOI: 10.1016/j.vaccine.2008.07.015

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  62 in total

1.  DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components.

Authors:  Ulrike K Hahn; Reinhard Boehm; Wolfgang Beyer
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

2.  Anthrax spores make an essential contribution to vaccine efficacy.

Authors:  Fabien Brossier; Martine Levy; Michèle Mock
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Characterization of the exosporium of Bacillus cereus.

Authors:  S Charlton; A J Moir; L Baillie; A Moir
Journal:  J Appl Microbiol       Date:  1999-08       Impact factor: 3.772

4.  Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Authors:  S F Little; B E Ivins; P F Fellows; A M Friedlander
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

5.  Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis.

Authors:  Christopher T Steichen; John F Kearney; Charles L Turnbough
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

Review 6.  Anthrax vaccines.

Authors:  A M Friedlander; S L Welkos; B E Ivins
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

8.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

9.  Identification of proteins in the exosporium of Bacillus anthracis.

Authors:  Caroline Redmond; Leslie W J Baillie; Stephen Hibbs; Arthur J G Moir; Anne Moir
Journal:  Microbiology       Date:  2004-02       Impact factor: 2.777

10.  Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging.

Authors:  Patrick Sanz; Louise D Teel; Farhang Alem; Humberto M Carvalho; Stephen C Darnell; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

View more
  17 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Localization and assembly of proteins comprising the outer structures of the Bacillus anthracis spore.

Authors:  Rebecca Giorno; Michael Mallozzi; Joel Bozue; Krishna-Sulayman Moody; Alex Slack; Dengli Qiu; Rong Wang; Arthur Friedlander; Susan Welkos; Adam Driks
Journal:  Microbiology (Reading)       Date:  2009-04       Impact factor: 2.777

Review 3.  The Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected Host.

Authors:  George C Stewart
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

4.  Bacillus cereus G9241 makes anthrax toxin and capsule like highly virulent B. anthracis Ames but behaves like attenuated toxigenic nonencapsulated B. anthracis Sterne in rabbits and mice.

Authors:  Melissa K Wilson; James M Vergis; Farhang Alem; John R Palmer; Andrea M Keane-Myers; Trupti N Brahmbhatt; Christy L Ventura; Alison D O'Brien
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

5.  Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system.

Authors:  Brian D McWilliams; Timothy Palzkill; George M Weinstock; Joseph F Petrosino
Journal:  Microb Pathog       Date:  2012-09-10       Impact factor: 3.738

6.  Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

Authors:  C K Cote; L Kaatz; J Reinhardt; J Bozue; S A Tobery; A D Bassett; P Sanz; S C Darnell; F Alem; A D O'Brien; S L Welkos
Journal:  J Med Microbiol       Date:  2012-07-05       Impact factor: 2.472

7.  Four superoxide dismutases contribute to Bacillus anthracis virulence and provide spores with redundant protection from oxidative stress.

Authors:  Robert J Cybulski; Patrick Sanz; Farhang Alem; Scott Stibitz; Robert L Bull; Alison D O'Brien
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

8.  Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge.

Authors:  Kanchan Sinha; Rakesh Bhatnagar
Journal:  Med Microbiol Immunol       Date:  2012-12-21       Impact factor: 3.402

9.  Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames.

Authors:  James M Vergis; Christopher K Cote; Joel Bozue; Farhang Alem; Christy L Ventura; Susan L Welkos; Alison D O'Brien
Journal:  Clin Vaccine Immunol       Date:  2012-10-31

10.  Identification of the UDP-N-acetylglucosamine 4-epimerase involved in exosporium protein glycosylation in Bacillus anthracis.

Authors:  Shengli Dong; Olga N Chesnokova; Charles L Turnbough; David G Pritchard
Journal:  J Bacteriol       Date:  2009-09-11       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.